• Skip to main content
  • Main Menu
  • Navigation for access to support pages
  • Navigation for access to legal pages
Logo Viva Technology
  • Session Recordings
  • Speakers
  • Exhibitors
  • FAQ
  • General Public Day
  • confirmation_numberGet Your 2026 Pass
  • Become an Exhibitor
Viva Technology

17-20 June 2026

Paris Expo Porte de Versailles

1 Place de la Porte de Versailles

F-75015 Paris France

More Infoarrow_right_alt

Event organizers

2025 ThemesConference ProgramOur Speakers

Exhibitors at VivaTech2025 Partners

Startups at VivaTechInvestors at VivaTech2025 Startup Challenges and Awards

JournalistsMedia Partners2025 PresskitPress Releases

About UsOur CommitmentsGeneral Public DayPractical Information

©Viva Technology 2016-2025 all rights reserved

Site MapSite noticeWebsite terms & conditionsB2B terms & conditionsData Privacy
  1. Logo Viva Technology
  2. Speakers
  3. Kimberly Powell
Photo Kimberly Powell

Kimberly Powell

Vice President of Healthcare and Life Sciences

NVIDIA

#
Connectivity, Cloud & Infrastructure
Artificial Intelligence
Healthcare & Wellness

About Me

Kimberly Powell is Vice President of Healthcare at NVIDIA. She's responsible for the company’s worldwide healthcare business, including hardware and software platforms for accelerated computing, AI, and visualization that power the ecosystem of medical imaging, life sciences, drug discovery, and healthcare analytics. Previously, Kimberly led the company’s higher education and research business, along with strategic evangelism programs, NVIDIA AI Labs, and the NVIDIA Inception program, with over 7,000 AI startup members. She joined NVIDIA in 2008 to establish NVIDIA GPUs as the accelerator platform for medical imaging instruments. She spent her early career in engineering and product management of diagnostic display systems at Planar Systems. Kimberly received a B.S. in electrical engineering with a concentration in computer engineering from Northeastern University in Massachusetts.

Hear My Insights

AI Drug Discovery: Curing with Code

As AI systems grow more capable in modeling complex biological systems, drug discovery is entering a new era — one where machine learning models don't just assist researchers, but actively generate hypotheses, design molecules, and predict therapeutic outcomes. This session explores the shift from traditional trial-and-error approaches to AI-driven methodologies that can integrate biological data at unprecedented scale and speed. What does it mean to have AI as a true collaborator in science? Can these systems unlock treatments for diseases that have eluded medicine for decades? As AI takes on a greater role in healthcare decision-making, how do we ensure that its use remains transparent, equitable, and ethically sound?